Immunomeinc
OpenManager, Clinical Supply Operations
- Location
- Bothell, Washington, United States
- Employment type
- Contract
- Posted
- Aug 3, 2026
- Last seen
- Aug 7, 2026
About the role
Company Overview
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.
Position Overview
The Manager, Clinical Supply Operations, is responsible for meeting Immunome’s supply requirements by enabling and overseeing cGMP operations performed at Contract Development and Manufacturing Organizations (CDMOs). This role centers on managing the supply of finished drug products (FDP) and may support a wide range of projects, including biologics and small molecule programs.
Responsibilities
- Serve as the Supplier Relationship Manager (SRM) for specified CDMOs offering clinical packaging and distribution services. Serve as the primary liaison between the CDMO and Immunome.
- Lead one or more Virtual Management Teams (VMTs) ensuring Immunome’s deliverables stay on track, and internal alignment on priorities and key communications with the CDMO.
- Conduct well-organized meetings with CDMOs. Ensure CDMO progress is tracking to plan (e.g., label development, production readiness, batch operations, release activities and logistics , etc.). Proactively address delays to avoid impact on supply.
- Participate in Clinical Operations study team(s) to stay current on trial design, demand parameters and protocol amendments. May support the development of randomization schemes for open and blind clinical studies. <li data-leveltext="·" data-font="Symbol" data-listid="29" data-list-defn-props="
